A Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of Q-122 for the Treatment of Vasomotor Symptoms in Female Breast Cancer Patients/Survivors Taking Tamoxifen or an Aromatase Inhibitor
Are you eligible to participate in this study?
You may be eligible for this study if you meet the following criteria:
Conditions: Vasomotor Symptoms | Breast Cancer
Age: Between 18 - 70 Years
In order to be eligible to take part in this trial, patients must meet the following criteria:
- Have a history of or current breast cancer and currently taking tamoxifen or an aromatase inhibitor.
- Experience an average of at least 50 moderate to severe hot flashes/week for the 2 weeks immediately preceding the Run-In Visit (i.e., during the Screening period).
For a full list of participation criteria, please visit clinicaltrials.gov.
Contact the research team to learn more about this study.
Fields marked with asterisk (*) are required